Revance Therapeutics Inc

RVNC

Equity

ISIN null / Valor 23239569

NASDAQ (2025-02-07)

USD 3.65%

Revance Therapeutics Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Revance Therapeutics Inc. is a biotechnology firm that specializes in the development and commercialization of innovative neuromodulator products for various therapeutic and aesthetic applications. The company has entered into strategic partnerships to expand its global footprint, notably with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (Fosun Pharma Industrial), granting Fosun Pharma Industrial exclusive rights to develop and commercialize Revance's daxibotulinumtoxinA-lanm injection in mainland China, Hong Kong, and Macau. This collaboration has led to the initiation of Phase 3 trials in China for the treatment of glabellar lines and cervical dystonia. Additionally, Revance is working with Viatris Inc. to develop a biosimilar to BOTOX®, aiming to compete in the short-acting neuromodulator market while also establishing a new category for longer-acting neuromodulators. This strategic approach underscores Revance's commitment to innovation and expanding access to its neuromodulator products in key markets worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-32.2%1Y

-73.1%3Y

-86.3%5Y

Performance

47.8%1Y

94.3%3Y

86.1%5Y

Volatility